As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

Trade secrets protect innovation by keeping that innovation secret. But trade secret protection is lost once the trade secret becomes known to the public. Biotechs should have a strategic plan for ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

The story of how Juan Ramón Alaix was groomed for his CEO role and how Zoetis turned into the world’s largest publicly traded animal health company.

As the use of AI increases and expands to new functional areas within biopharmaceutical companies, leaders must understand the risks and mitigate the impact of hallucinations in AI model outputs.

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS ...

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.

Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful ...